代表性论文 (*通讯作者，#共同第一作者)

1. Chen T#, Ni N#, Yuan L#, Xu L, Bahri N, Sun B, Wu Y, Ou WB*. Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling. Front Pharmacol. 2021, 12:686874. (IF 5.81)

2.  Ou WB*#, Lundberg MZ#, Zhu S, Bahri N, Kyriazoglou A, Xu L, Chen T, Mariño-Enriquez A, Fletcher JA*. YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways. Oncogenesis. 2021, 10(5):37. (IF 7.485)

3.  Yuan L, Sun B, Xu L, Chen L, Ou WB*. The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma. Int. J Mol. Sci. 2021, 22(14): 7416 (IF 5.923)

4. Salah A, Wang H, Ji M, Ou WB, Qi N, Wu Y*. Insights into Dendritic cells in cancer immunotherapy: From bench to clinical applications. Frontiers in Cell and Developmental Biology. 2021 9:686544. (IF 6.684)

5. Song W, Wang H, Lu M, Ni X, Bahri N, Zhu S, Chen L, Wu Y, Qiu J, Fletcher JA and Ou WB*. AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression. Cancers 2020, 12, 2757 (IF 6.639)

6. Zhu C, Zhuang W, Chen L, Yang W, Ou WB*. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Translational Lung Cancer Research. 2020, 9: 111-138. (IF 6.498)

7.  Huang M #, Yang W#, Zhu J#, Mariño-Enríquez A, Zhu Chen, Chen J, Wu Y, Quan Y, Qiu HB, Li X, Chai L, Fletcher JA, and Ou WB*. Coordinated Targeting CK2 and KIT in Gastrointestinal Stromal Tumors. Br J Cancer 2020, 122:372–381. (IF 7.64)

8. Ou WB*, Ni N, Zuo R, Zhuang W, Zhu MJ, Kyriazoglou A, Wu D, Eilers G, Demetri GD, Qiu H, Li B, Marino-Enriquez A, Fletcher JA*. Cyclin D1 is a Mediator of Gastrointestinal Stromal Tumor KIT-independence. Oncogene. 2019, 38: 6615-6629. (IF 9.8)

9. Cao ZF, Gao Q, Fu M, Ni N, Pei Y, Ou WB*. Anaplastic lymphoma kinase fusion: role in cancers and therapeutic perspective. Oncology Letters 2019, 17(2): 2020-2030. (IF 1.664)

10.  Tu Y#, Zuo R#, Ni N#, Eilers G, Wu D, Pei Y, Nie Z, Wu Y, Wu Y, and Ou WB*. Activated Tyrosine Kinases in Gastrointestinal Stromal Tumor with Loss of KIT Oncoprotein Expression. Cell cycle 2018, 17(23): 2577-2592 (IF3.3）

11. He Q*, Huang S, Wu Y, Zhang W, Wang F, Cao J, Sheng Q, Liang Z, Liu L, and Ou WB*. Comparative study on the composition of free amino acids and derivatives in the two botanical origins of an edible Chinese herb“Xiebai”, i.e., Allium chinense G. Don and Allium macrostemon Bunge species. Food Research International, 2018, 106: 446-457. (IF3.52）

12. Liu XL, Zuo R, Ou WB*. The hippo pathway provides novel insights into lung cancer and mesothelioma treatment. J Cancer Res Clin Oncol. 2018, 144: 2097–2106. (IF3.282）

13.  Chen W#, Kuang Y#, Qiu H#, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li H, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, and Ou WB*. Dual Targeting of Insulin Receptor and KIT in ImatinibResistant Gastrointestinal Stromal Tumors. Cancer Res. 2017, 77：5107~5117. (IF 9.112)

14.  Ou WB*, Lu M, Eilers G, Li H, Ding J, Meng X, Wu Y, He Q, Sheng Q, Zhou HM, and Fletcher J A. Co-targeting of FAK and MDM2 Triggers Additive Anti-proliferative Effects in Mesothelioma via a Coordinated Reactivation of p53. Br J Cancer 2016, 115: 1253-1263 (IF 6.12)

15.  Yong KJ#, Li A#, Ou WB#, Hong CK, Zhao W, Wang F, Tatetsu H, Yan B, Qi L, Fletcher JA, Yang H, Soo R, Tenen DG, Chai L. Targeting SALL4 by entinostat in lung cancer. Oncotarget. 2016, 7(46): 75425-40 (IF 5.168).

16.  Lee JC, Li CF, Huang HY, Zhu MJ, Mariño-Enríquez A, Lee CT, Ou WB, Hornick JL, and Fletcher JA. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J. Pathology. 2016, 241(3):316-323. (IF 7.381)  

17.Yang P, Chen W, Li X, Eilers G, He Q, Liu L, Wu YQ, Wu YH, Yu W, Fletcher JA, Ou WB*,. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3. Oncotarget 2016，7(22):32652-63. (IF 5.009)

18.  Ou WB*, Zhu J, Eilers G, Liu L, Kuang Y, Marino-Enriquez A, Li XH, Li HL, Meng FG, Zhou HM, Sheng Q, and Fletcher JA. HDACi inhibits liposarcoma via Targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status. Oncotarget 2015, 6(12):10510-20. (IF 6.3587)

19.   Zhu JQ and Ou WB* “Therapeutic Targets in Gastrointestinal Stromal Tumors” (Review) World Journal of Translational Medicine 2015, 4(1): 25-37.

20.  Zhou SM, Liu L, Li HL, Eilers G, Shi S, Yan ZQ, Corson JM., Meng FG, Zhou HM, Sheng Q, Fletcher JA, Ou WB*. Multipoint Targeting of the PI3K/mTOR Pathway in Mesothelioma. Br J Cancer 2014, 110: 2479-88. (IF 5.082)

21.  Marino-Enriquez A, Ou WB, Cowley G, Luo B, Jonker A, Mayeda M, Okamoto M, Eilers G, Czaplinski J, Sicinska E, Wang YX, Taguchi T, Demetri G, Root D, Fletcher JA. Genome-Wide Functional Screening Identifies CDC37 as a Crucial HSP90-cofactor for KIT Oncogenic Expression in Gastrointestinal Stromal Tumor. Oncogene , 2014，33(14):1872-6. (IF 8.559).

22.  Lee CH#, Ou WB#, Mariño-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, Gilks CB, Yaffe MB, Prentice LM, McPherson A, Jones SJ, Marra MA, Shah SP, van de Rijn M, Huntsman DG, Dal Cin P, Debiec-Rychter M, Nucci MR, Fletcher JA. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A. 2012，109(3):929-34. (IF 9.809)

23. Ou WB*, Yi T, Kim JM, Khorana HG*. The roles of Transmembrane Domains Helix-III during Rhodopsin photoactivation. PLoS ONE 2011, 6:e17398. (IF 3.73)

24. Ou WB*, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA*. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia. 2011, 13(1):12-22. (IF 5.47)

25. Mariño-Enríquez A#, Ou WB#, Weldon CB, Fletcher JA, Pérez-Atayde AR. ALK Rearrangement in Sickle Cell Trait-Associated Renal Medullary Carcinoma. Genes, Chromosomes & Cancer 2011, 50: 146-53. (IF 3.546)

26.  Ou WB*, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ, Fletcher JA*. AXL regulates mesothelioma proliferation and invasivness. Oncogene 2011，30: 1643-52. (IF 8.559)

27. Jiao Y, Ou W, Meng F, Zhou H, Wang A. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol Cancer. 2011, 10:125.

28. Ou WB*, Zhu MJ, Demetri GD, Fletcher CD, Fletcher JA*. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene 2008, 27: 5624-34. (IF 8.559)

29. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008, 26:5352-9. (IF 17.879)

30. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 2006, 24: 4764-74. (IF 17.879)

31. Rossi S, Ou W, Tang D, Bhattacharya N, Dei Tos AP, Fletcher JA, Loda M. Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol. 2006 Jul; 209(3):369-75. (IF 7.585)

32.  Zhao TJ#, Ou WB#, Xie Q, Liu Y, Yan YB, and Zhou HM. Catalysis of creatine kinase refolding by protein disulphide isomerase involves disulphide cross-link and dimer to tetramer switch. J. Biol. Chem. 2005, 280: 13470-76. (IF 4.651)